Enbrel Articles
Wyeth's Enbrel effective in AS
30 June 2003
Wyeth's Enbrel effective in AS
30 June 2003
Takeda/Wyeth abandon JV
26 May 2003
Amgen outperforms in 1st qtr, raises forecast
28 April 2003
Canadian province OKs TNF blockers
7 April 2003
Abbott starts Humira trials in psoriasis
17 March 2003
Update: Biogen gets US approval for Amevive
10 February 2003
Biogen's Amevive cleared for psoriasis
10 February 2003
Stock Commentary - week to Jan 20 - New York
27 January 2003
Amgen files Enbrel for spondylitis
27 January 2003
Update - Amgen says Enbrel psoriasis trial is positive
27 January 2003
Amgen says Enbrel clears Ph III psoriasis trial
27 January 2003
New York Stock Commentary - 2 weeks to Dec 30
6 January 2003
XOMA/Genentech file Raptiva BLA in USA
6 January 2003
FDA filings in brief
6 January 2003
Abbott gets approval for blockbuster candidate Humira in USA
6 January 2003
US FTC OKs Amgen/Immunex merger
22 July 2002
Wyeth hit as Prempro linked to cancer, CVD
15 July 2002
Stock Commentary - New York
3 June 2002
UK NICE OKs Remicade for some Crohn's cases
13 May 2002
Stock Commentary - New York
6 May 2002
Immunex 1st-qtr revenues rose 25%
29 April 2002
US insurers requiring prior OK for COX-2s
25 March 2002
UK NICE's proposed guidance timetable
25 March 2002
Zymogenetics sues Immunex over Enbrel
18 March 2002
Enbrel also active in psoriasis, says study
4 March 2002
Enbrel linked to lupus, says Lancet letter
25 February 2002
Funding and approving new drugs in Israel's NHI basket
18 February 2002
Immunex' Enbrel cleared for psoriatic arthritis.
21 January 2002
Rheumatoid arthritis market forecasts
14 January 2002
Amgen planning to acquire Immunex Corp in $18 billion deal?
7 January 2002
Stock Commentary - New York
7 January 2002
Amgen planning to acquire Immunex Corp in $18 billion deal?
7 January 2002
Amgen confirms $16 billion bid for Immunex
7 January 2002
Amgen planning to acquire Immunex Corp in $18 billion deal?
18 December 2001
Amgen planning to acquire Immunex Corp in $18 billion deal?
14 December 2001
Actelion licenses Tracleer to Neopharm in Israel
12 December 2001
Stock Commentary - New York
6 December 2001
Amgen's Kineret cleared in first market
16 November 2001
Enbrel effective in psoriatic arthritis
14 November 2001
New safety data on Amgen's Kineret bode well for its use in RA
14 November 2001
Immunex building $450 mill facility
8 November 2001
Remicade increases mortality in CHF trial
23 October 2001
Amevive out in front amongst new biologicals for psoriasis
16 October 2001
Enbrel to be fast-tracked for new indication
19 September 2001
Immunex appointments
13 September 2001
Immunex' share price boosted by positive Ph II Enbel data
23 August 2001
TNF-alpha inhibitor sales forecast to soar
22 August 2001
Amgen boosted by FDA committee recommendation
20 August 2001
FDA advisory panel meetings
16 August 2001
Stock Commentary - New York
16 August 2001
Immunex and Wyeth initiate RA trial
15 August 2001
Celltech reaches target with arthritis drug
30 July 2001
Immunex' Enbrel filed for psoriatic arthritis
17 July 2001
New AHP CEO reviews growth strategy
25 May 2001
Stock Commentary - New York
5 April 2001
US HMOs reveal their most-accepted drugs
5 April 2001
Stock Commentary - New York
29 March 2001
AtheroGenics plans trials of arthritis drug
28 February 2001
Immunex drops plans to develop Enbrel for Crohn's disease
14 February 2001
Strong 2000 results for Immunex
26 January 2001
Stock Commentary - New York
14 December 2000
Enbrel approved in Canada
14 December 2000
Market forecasts for arrythmia, CHD drugs
29 November 2000
BASF excited about prospects for D2E7, as rumor mill talks of pharma
15 November 2000
FDA to strengthen warnings on Enbrel and Remicade?
2 November 2000
Immunex' Enbrel shows long-term use
30 October 2000
AHP reaping benefits of R&D spend
20 October 2000
EMEA warns of blood disorder with Enbrel
5 October 2000
Bullish forecast for pharma industry from Merrill Lynch, despite patent
29 September 2000
Actelion well-placed for success with endothelin antagonists for heart
21 September 2000
Immunex' Nuvance limited to severe asthma
25 August 2000
First-half sales rise 19% at Boeh Ingelheim
25 August 2000
Immunex's Enbrel promise in psoriatic arthritis
10 August 2000
AHP posts healthy 2nd quarter results
24 July 2000
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
